GSK PLC (GSK)
41.24
+0.65
(+1.60%)
USD |
NYSE |
Apr 23, 16:00
41.25
+0.01
(+0.02%)
After-Hours: 20:00
GSK Cash from Investing (Quarterly): 374.35M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 374.35M |
| September 30, 2023 | -641.75M |
| June 30, 2023 | -1.221B |
| March 31, 2023 | -495.92M |
| December 31, 2022 | -1.174B |
| September 30, 2022 | -4.486B |
| June 30, 2022 | -381.49M |
| March 31, 2022 | -4.821B |
| December 31, 2021 | -492.34M |
| September 30, 2021 | -1.627B |
| June 30, 2021 | -259.51M |
| March 31, 2021 | -66.17M |
| December 31, 2020 | -86.19M |
| September 30, 2020 | -579.08M |
| June 30, 2020 | 3.513B |
| March 31, 2020 | -74.34M |
| December 31, 2019 | -695.22M |
| September 30, 2019 | -337.19M |
| June 30, 2019 | -655.45M |
| March 31, 2019 | -5.148B |
| December 31, 2018 | -587.09M |
| September 30, 2018 | -622.40M |
| June 30, 2018 | -346.72M |
| March 31, 2018 | -515.88M |
| December 31, 2017 | -412.75M |
| Date | Value |
|---|---|
| September 30, 2017 | -624.61M |
| June 30, 2017 | -579.33M |
| March 31, 2017 | -246.47M |
| December 31, 2016 | -281.06M |
| September 30, 2016 | -115.35M |
| June 30, 2016 | -368.14M |
| March 31, 2016 | -954.82M |
| December 31, 2015 | -787.36M |
| September 30, 2015 | -148.34M |
| June 30, 2015 | -585.19M |
| March 31, 2015 | 10.75B |
| December 31, 2014 | -609.93M |
| September 30, 2014 | -354.19M |
| June 30, 2014 | -260.20M |
| March 31, 2014 | -552.63M |
| December 31, 2013 | 2.842B |
| September 30, 2013 | -827.03M |
| June 30, 2013 | -732.11M |
| March 31, 2013 | -462.90M |
| December 31, 2012 | -409.51M |
| September 30, 2012 | -3.802B |
| June 30, 2012 | -183.44M |
| March 31, 2012 | 226.19M |
| December 31, 2011 | -746.38M |
| September 30, 2011 | -381.08M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-4.821B
Minimum
Mar 2022
3.513B
Maximum
Jun 2020
-747.70M
Average
-495.92M
Median
Mar 2023
Cash from Investing (Quarterly) Benchmarks
| AstraZeneca PLC | -1.077B |
| Haleon PLC | -- |
| Novo Nordisk A/S | -2.112B |
| Pfizer Inc | -11.00B |
| Sanofi SA | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.899B |
| Cash from Financing (Quarterly) | -4.425B |
| Free Cash Flow | 5.505B |
| Free Cash Flow Per Share (Quarterly) | 1.436 |
| Free Cash Flow to Equity (Quarterly) | 6.965B |
| Free Cash Flow to Firm (Quarterly) | 3.286B |
| Free Cash Flow Yield | 6.13% |